Us was Pharming’s largest region in fiscal 2025, bringing in $361.75M of $376.13M (96%).
| Geography | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| Us | $200.08M | $239.11M | $287.15M | $361.75M | ||||
| U.S | — | — | — | — | ||||
| Europe & Row | $5.54M | $6.21M | $10.05M | $14.39M | ||||
| Europe | — | — | — | — | ||||
| Row | — | — | — | — | ||||
| Total | $205.62M | $245.32M | $297.20M | $376.13M |
Pharming brought in $376.13M from its two regions in fiscal 2025, the year ended December 31, 2025. That was up 26.6% from $297.20M in fiscal 2024. Us was the largest at $361.75M (96.2%), ahead of Europe & Row at $14.39M (3.8%).
Compared with fiscal 2024, Europe & Row grew 43.1% to $14.39M and Us grew 26.0% to $361.75M. From fiscal 2022 to 2025, combined revenue from these regions grew from $205.62M to $376.13M, a compound annual growth rate of 22.3%. Us' share of the total fell from 97.3% to 96.2%.
Ruconest was Pharming’s largest revenue line in fiscal 2025, bringing in $317.92M of $376.13M (85%).
| Products and services [axis] | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Ruconest | $205.62M | $227.13M | $252.24M | $317.92M | |
| Joenja | — | $18.20M | $45.00M | $58.21M | |
| Total | $205.62M | $245.33M | $297.24M | $376.13M |
Pharming brought in $376.13M from its two revenue lines in fiscal 2025, the year ended December 31, 2025. That was up 26.5% from $297.24M in fiscal 2024. Ruconest was the largest at $317.92M (84.5%), ahead of Joenja at $58.21M (15.5%).
Compared with fiscal 2024, Joenja grew 29.4% to $58.21M and Ruconest grew 26.0% to $317.92M.
Pharming began breaking out Joenja in fiscal 2023, when it brought in $18.20M.
Pharming (PHAR) reports its revenue by geography and by products and services [axis]. In fiscal 2025, Us was its largest region, bringing in $361.75M (96.2% of the total), followed by Europe & Row at $14.39M (3.8%).
Us was Pharming's largest region in fiscal 2025, bringing in $361.75M, or 96.2% of the $376.13M total across its two regions.
Ruconest was Pharming's largest revenue line in fiscal 2025, bringing in $317.92M, or 84.5% of the $376.13M total across its two revenue lines.
Europe & Row grew faster than Us in fiscal 2025, up 43.1% from $10.05M to $14.39M. Us grew 26.0% to $361.75M.
Every figure comes from Pharming's annual financial filings, as reported. Each line keeps the name Pharming gives it, and years follow its fiscal calendar.
Pharming's revenue by geography goes back to fiscal 2018, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.